BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31827136)

  • 1. Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.
    Fujiwara H; Tateishi K; Misumi K; Hayashi A; Igarashi K; Kato H; Nakatsuka T; Suzuki N; Yamamoto K; Kudo Y; Hayakawa Y; Nakagawa H; Tanaka Y; Ijichi H; Kogure H; Nakai Y; Isayama H; Hasegawa K; Fukayama M; Soga T; Koike K
    Sci Rep; 2019 Dec; 9(1):18859. PubMed ID: 31827136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
    Saha SK; Parachoniak CA; Ghanta KS; Fitamant J; Ross KN; Najem MS; Gurumurthy S; Akbay EA; Sia D; Cornella H; Miltiadous O; Walesky C; Deshpande V; Zhu AX; Hezel AF; Yen KE; Straley KS; Travins J; Popovici-Muller J; Gliser C; Ferrone CR; Apte U; Llovet JM; Wong KK; Ramaswamy S; Bardeesy N
    Nature; 2014 Sep; 513(7516):110-4. PubMed ID: 25043045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH mutations in liver cell plasticity and biliary cancer.
    Saha SK; Parachoniak CA; Bardeesy N
    Cell Cycle; 2014; 13(20):3176-82. PubMed ID: 25485496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
    Yang H; Ye D; Guan KL; Xiong Y
    Clin Cancer Res; 2012 Oct; 18(20):5562-71. PubMed ID: 23071358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
    Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
    Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
    Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP
    Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
    Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
    Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.
    Ye D; Guan KL; Xiong Y
    Trends Cancer; 2018 Feb; 4(2):151-165. PubMed ID: 29458964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.
    Navis AC; Niclou SP; Fack F; Stieber D; van Lith S; Verrijp K; Wright A; Stauber J; Tops B; Otte-Holler I; Wevers RA; van Rooij A; Pusch S; von Deimling A; Tigchelaar W; van Noorden CJ; Wesseling P; Leenders WP
    Acta Neuropathol Commun; 2013 May; 1():18. PubMed ID: 24252742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
    Bhavya B; Anand CR; Madhusoodanan UK; Rajalakshmi P; Krishnakumar K; Easwer HV; Deepti AN; Gopala S
    Cell Mol Neurobiol; 2020 Jan; 40(1):53-63. PubMed ID: 31485826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of both mitochondrial isocitrate dehydrogenase enzymes in pancreatic beta cells inhibits insulin secretion.
    MacDonald MJ; Brown LJ; Longacre MJ; Stoker SW; Kendrick MA; Hasan NM
    Biochim Biophys Acta; 2013 Nov; 1830(11):5104-11. PubMed ID: 23876293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
    Losman JA; Kaelin WG
    Genes Dev; 2013 Apr; 27(8):836-52. PubMed ID: 23630074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.
    Wang P; Wu J; Ma S; Zhang L; Yao J; Hoadley KA; Wilkerson MD; Perou CM; Guan KL; Ye D; Xiong Y
    Cell Rep; 2015 Dec; 13(11):2353-2361. PubMed ID: 26686626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
    Grassian AR; Lin F; Barrett R; Liu Y; Jiang W; Korpal M; Astley H; Gitterman D; Henley T; Howes R; Levell J; Korn JM; Pagliarini R
    J Biol Chem; 2012 Dec; 287(50):42180-94. PubMed ID: 23038259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
    Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
    Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells.
    Badur MG; Muthusamy T; Parker SJ; Ma S; McBrayer SK; Cordes T; Magana JH; Guan KL; Metallo CM
    Cell Rep; 2018 Oct; 25(4):1018-1026.e4. PubMed ID: 30355481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.
    Seltzer MJ; Bennett BD; Joshi AD; Gao P; Thomas AG; Ferraris DV; Tsukamoto T; Rojas CJ; Slusher BS; Rabinowitz JD; Dang CV; Riggins GJ
    Cancer Res; 2010 Nov; 70(22):8981-7. PubMed ID: 21045145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.